Enzo Biochem is a diagnostics & research business based in the US. Enzo Biochem shares (ENZ) are listed on the NYSE and all prices are listed in US Dollars. Enzo Biochem employs 179 staff and has a trailing 12-month revenue of around $33.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.17 |
|---|---|
| 52-week range | $0.99 - $1.71 |
| 50-day moving average | $1.12 |
| 200-day moving average | $1.25 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.35 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.17 from 2024-07-22
| 1 week (2024-07-17) | 1.17 |
|---|---|
| 1 month (2024-06-24) | 6.36% |
| 3 months (2024-04-24) | 10.38% |
| 6 months (2024-01-24) | -10.00% |
| 1 year (2023-07-24) | -13.97% |
|---|---|
| 2 years (2022-07-22) | -54.65% |
| 3 years (2021-07-23) | 3.13 |
| 5 years (2019-07-24) | 3.94 |
| Revenue TTM | $33.3 million |
|---|---|
| Gross profit TTM | $11.6 million |
| Return on assets TTM | -12.77% |
| Return on equity TTM | -39.9% |
| Profit margin | 134.17% |
| Book value | $1.35 |
| Market Capitalization | $58.7 million |
TTM: trailing 12 months
We're not expecting Enzo Biochem to pay a dividend over the next 12 months.
Enzo Biochem's shares were split on a 105:100 basis on 20 October 2004. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your Enzo Biochem shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Enzo Biochem shares which in turn could have impacted Enzo Biochem's share price.
Over the last 12 months, Enzo Biochem's shares have ranged in value from as little as $0.9901 up to $1.7099. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enzo Biochem's is 0.76. This would suggest that Enzo Biochem's shares are less volatile than average (for this exchange).
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora. com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.